HEALTH

Harvard Heart Letter: Many consumers who supplement with aspirin don’t need to

BY Michael Johnsen

BOSTON — Fewer than half of people who could benefit from the heart-health benefits of a daily low-dose aspirin take it, while many others take it when they shouldn’t, the January 2014 Harvard Heart Letter reported Friday.

If you don’t have heart disease, but do have high blood pressure, diabetes or other risk factors for heart disease, don’t automatically assume that taking aspirin every day is a good idea, the Letter noted. "A lot of people take aspirin who really shouldn’t," stated Christopher Cannon, a cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School. "Everyone assumes aspirin is harmless, but it isn’t." 

For some, the downsides of aspirin — mainly gastrointestinal bleeding — outweigh its benefits. Taking aspirin with food may help. So can taking medications to treat heartburn, which help protect the stomach. These include simple antacids like Tums, acid blockers like famotidine (Pepcid) or proton-pump inhibitors, such as omeprazole (Prilosec OTC, Zegerid OTC). 

A pill that combines aspirin and omeprazole may soon be available, the Letter suggested.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA advisory committee to consider OTC NDA for asthma-relieving Primatene HFA

BY Michael Johnsen

SILVER SPRING, Md. — The Nonprescription Drugs Advisory Committee on Thursday announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA, an epinephrine inhalation aerosol 125 microgram (mcg)/actuation, as a temporary reliever of mild symptoms of intermittent asthma for consumers 12 years of age and older. 

The epinephrine inhaler was developed as a replacement for Primatene Mist (epinephrine metered inhaler 200 mcg/actuation), an OTC product that was phased out in December 2011 because of the use of chlorofluorocarbons as the propellant.  

The committee will be asked to consider whether the data support an acceptable risk/benefit profile of the epinephrine inhaler for use by OTC consumers.

The following day, the committee will meet to discuss whether OTC bronchodilators administered by hand-held rubber bulb nebulizers for the temporary relief of mild symptoms of intermittent asthma (shortness of breath, tightness of chest, and wheezing) should be removed from the monograph altogether. Specific drugs to be discussed include epinephrine, epinephrine bitartrate and racepinephrine hydrochloride.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

GSK Consumer Healthcare launches ’60-Day Kickstart’ campaign for weight loss

BY Alaric DeArment

PARSIPPANY, N.J. — GlaxoSmithKline is offering a new online campaign under the Alli brand to support healthy weight-loss resolutions, the company said Thursday.

GSK Consumer Healthcare announced the launch of the 60-Day Kickstart campaign that offers free support for starting a healthy, balanced diet for the new year. Benefits offered include two months of free, motivational tips and reminders; accessibility and encouragement from New York-registered dietician Betty Kovacs; exclusive, balanced gourmet recipes that align with the Alli diet plan; and an open community and social forum for support.

"For many, New Year’s is all about starting over and being smarter about your diet, Alli brand marketing director Deborah Larsen said. "As part of the program, the Alli brand has teamed up with celebrity chef, restauranteur and author Richard Blais for exclusive, easy, healthy recipes and New York-registered dietician Betty Kovacs, who will be making regular appearances online and offering her expert advice."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?